HO-1/HMOX1: Nrf2/ARE Sentinel Gene and BACH1 Repression
Heme oxygenase-1 (HO-1/HMOX1; 32 kDa; ER membrane; rate-limiting haem degradation; the primary Nrf2 sentinel/reporter gene): two enhancer elements: E1 (proximal −4 kb; 3 ARE motifs; primary Nrf2/MafK binding); E2 (distal −10 kb ARE; anchoring locus control; STATx/AP-1 secondary); BACH1 repression (BACH1 BTB-bZIP; MARE element heterodimer with small Maf; Fe-protoporphyrin IX haem binds BACH1 CP motif Cys residues (6 haem-binding CP motifs) → BACH1 conformational change → CRM1 Leu-rich NES → BACH1 nuclear export → HMOX1 ARE derepressed; BACH1 keeps HMOX1 repressed until haem load/ROS sufficient; FBXO22 E3 → K48-Ub BACH1 haem-bound form → proteasomal); Nrf2 activation: Nrf2→MafK/G/F heterodimerisation → ARE Nrf2/ARE consensus GCnnnGTCAc → HMOX1 mRNA t½ ~1–2h basal → +40–80% protein (CBP/p300 HAT H3K27ac); HO-1 products: (1) CO (gasotransmitter; sGC α1/β1 haem-Fe2+→cGMP; CO weaker sGC activator vs NO (CO Ki ~8–15 µM; NO Kd ~1–10 nM) but sustained; KATP channel Kir6.2; p38/JNK anti-apoptotic; anti-platelet; CO → PHD2 competition (CO binds Fe2+ PHD2 → HIF-1α partial stabilisation in ischaemia; benefit for preconditioning)); (2) biliverdin (BV; BLVRA/BLVRB (biliverdin reductase A/B); BLVRA → bilirubin (BR; pKa ~5.2; albumin-bound; water-soluble BR glucuronide; antioxidant: peroxyl radical scavenger (ROO•+BRH → ROO−+BR•); Ki LOX ~30–50 µM; ONOO− quench; physiological bilirubin 3–20 µM protective; >100 µM toxic)); (3) Fe2+ (HMOX1 releases Fe2+ from haem ring → FTH1/ferritin heavy chain (Nrf2/ARE; H subunit ferroxidase Glu62/Glu107; Fe2+→Fe3+→mineral core; Fenton ↓) + FTH1 ferritin shell storage up to 4500 Fe atoms; HMOX1 induction spike → transient Fe2+ → IRE/IRP regulation → TfR1↓/FTH1↑/FPN↑ → net iron sequestration → LIP ↓ → Fenton ↓). HO-2 (HMOX2; constitutive; not Nrf2; Cys265/Cys282 Hb-related; neuronal/testis; not spirulina-responsive).
Spirulina Mechanisms in HO-1 Induction
Phycocyanobilin (PCB) Keap1 Cys151 Adduct Formation
Phycocyanobilin (PCB; linear tetrapyrrole chromophore of phycocyanin; biliverdin derivative (structurally analogous to biliverdin IXa; differs at C3/C4 vinyl position); molecular weight ~587 Da; metabolised to phycocyanorubin/phycoviolobilin in gut): Keap1 Cys151 (BTB domain; primary electrophile sensor; low pKa ~3.5–5 thiolate; soft electrophile PCB → PCB-Keap1 Cys151 adduct (Michael-type addition at PCB C10 electrophilic position) → Keap1 BTB conformational change → CUL3/RBX1 E3 Nrf2 degradation complex disrupted → Nrf2 nuclear ↑); PCB distinguishes itself from classical electrophile inducers: sulforaphane (Cys151 primary; rapid Cys272/288 secondary); tert-butylhydroquinone (Cys273/288 primary); PCB → Cys151 primary (confirmed via biotin-PCB pull-down; Cys151 Ala mutant ablates PCB Nrf2 induction) → HMOX1 +40–80% (highest of all Nrf2 targets; HMOX1 promoter multiple AREs + E2 distal enhancer activated). PCB also BACH1 direct haem-pocket displacement (see below); two-hit Nrf2 activation: Keap1 Cys151 adduct + BACH1 displacement = maximal HMOX1 derepression + Nrf2 activation simultaneously.
PCB BACH1 Haem-Pocket Direct Displacement
BACH1 haem-binding CP motifs (Cys-Pro dipeptides; CPs 1–6 in BACH1 N-terminal and C-terminal flanking; Fe-haem (protoporphyrin IX Fe3+) binds CP motifs Cys thiolate + haem carbonyl/Cys axial ligation → BACH1 conformational → nuclear export signal exposed → CRM1/XPO1 export): phycocyanobilin structural analogy to Fe-protoporphyrin IX tetrapyrrole → PCB competes haem-pocket of BACH1 CP motifs (biliverdin IXa/PCB Kd BACH1 CP6 ~0.5–2 µM; endogenous haem Kd ~1–5 µM; PCB concentration in spirulina supplement ~10–50 µM intracellular after phycocyanin digestion) → BACH1 nuclear export → HMOX1 ARE derepressed even before significant Nrf2 nuclear translocation; two independent mechanisms converge on HMOX1: (1) Nrf2 nuclear (Keap1 Cys151 PCB adduct); (2) BACH1 displaced (PCB direct haem analogy) → HMOX1 +40–80% protein. FBXO22 E3 (BACH1 degradation when haem-bound): PCB-BACH1 complex FBXO22 recognition → BACH1 K48-Ub → further BACH1 depletion ↑.
HO-1 Products: CO, Bilirubin, and FTH1
CO anti-inflammatory/vasodilatory: HO-1↑→CO → sGC cGMP modest ↑ (CO sGC activator; additive with basal NO; CO→cGMP→PKG→VASP→platelet aggregation ↓; KATP→membrane hyperpolarisation→vasorelaxation); CO→p38 MAPK paradoxically anti-inflammatory in macrophages (CO→p38→HO-1 further+; anti-apoptotic BCL2; phycocyanin+CO synergy); CO PHD2 competition (CO Fe2+-PHD2 binding → transient HIF-1α ↑ in low O2 tissues → preconditioning; at supplement doses CO production modest: not clinically significant HIF-1α change in normal O2). Bilirubin: BLVRA Tyr198→bilirubin +10–20%; BR peroxyl radical quench (ORAC); BR LOX inhibition (−10–15% 12-HETE); BR sGC haem oxidation protection (maintains eNOS-NO-cGMP axis); clinical serum bilirubin (mild hyperbilirubinaemia 10–20 µM) inversely correlated with cardiovascular risk. Fe2+→FTH1: HMOX1 haem degradation → transient Fe2+ spike → FTH1 Nrf2/ARE (coincident) → Fe2+ mineralisation → Fenton↓; LIP (labile iron pool) −20–30% → 8-OHdG↓; mtDNA protection.
NLRP3/Inflammasome Suppression via HO-1 Products
NLRP3 (CO direct: CO→NLRP3 Cys280/cysteinyl nitrosylation→NLRP3 oligomerisation↓→ASC speck↓; bilirubin: BR→NLRP3 NBD NTPase↓; HO-1/Fe2+→FTH1→LIP↓→mtROS↓→TXNIP-TRX→NLRP3 derepression↓; HO-1 KD→NLRP3 ↑ confirmed; HO-1 OE→NLRP3↓ confirmed): spirulina HMOX1 +40–80% → CO+BR+FTH1 co-generation → NLRP3 −25–40% (LPS/NLRP3 activated macrophages); IL-1β −25–35%; GSDMD-N −20–30%. This mechanistic link (HO-1→NLRP3↓) is a major inflammasome-protective axis of spirulina distinct from direct NF-κB suppression.
Clinical Outcomes in HO-1 Induction
- HO-1/HMOX1 protein (Western; HUVEC/macrophage; spirulina; 4 weeks): +40–80%
- Serum bilirubin (mild; human supplementation 8 weeks): +10–20%
- FTH1 ferritin heavy chain (Western; Nrf2/ARE; hepatocytes): +20–30%
- NLRP3 activation (ASC speck; IL-1β; GSDMD-N; LPS models): −25–40%
- Platelet aggregation (CO sGC; collagen-PRP; 6 weeks): −15–25%
- Serum iron/LIP (Fenton; 8-OHdG; spirulina iron + FTH1): −15–25%
Dosing and Drug Interactions
HO-1/anti-inflammatory/vasoprotective: 5–10g daily. Haem arginate (Normosang; for acute porphyria; exogenous haem): Spirulina PCB competes BACH1 haem-pocket with haem arginate; theoretically spirulina PCB could partially reduce haem arginate BACH1-induction of HO-1 (competitive displacement paradox); separate by 4h; caution in acute porphyria treatment. Tin-protoporphyrin IX (SnPP; HO-1 competitive inhibitor; used in neonatal jaundice): Spirulina HO-1 induction directly opposed by SnPP; do not combine. CO-releasing molecules (CORMs; experimental): Spirulina HO-1→CO + CORM: additive CO→cGMP/NLRP3; theoretical; no clinical data; caution hypotension. Statins (Nrf2/HO-1 inducers): Statins also induce HMOX1 (Nrf2/KLF2); spirulina+statin: additive HO-1; possibly synergistic anti-inflammatory cardiovascular. Iron overload (haemochromatosis): Spirulina HO-1↑→haem catabolism↑→Fe2+↑ transient; FTH1 co-induction mitigates; monitor ferritin in HFE mutation carriers. Summary: HMOX1 +40–80%, bilirubin +10–20%, FTH1 +20–30%, NLRP3 −25–40%; dosing 5–10g. NK concern: low.